MX2021003136A - Conjugados de proteinas de union a toxinas que comprenden antraciclinas, y uso de los mismos en aplicaciones inmunooncologicas. - Google Patents
Conjugados de proteinas de union a toxinas que comprenden antraciclinas, y uso de los mismos en aplicaciones inmunooncologicas.Info
- Publication number
- MX2021003136A MX2021003136A MX2021003136A MX2021003136A MX2021003136A MX 2021003136 A MX2021003136 A MX 2021003136A MX 2021003136 A MX2021003136 A MX 2021003136A MX 2021003136 A MX2021003136 A MX 2021003136A MX 2021003136 A MX2021003136 A MX 2021003136A
- Authority
- MX
- Mexico
- Prior art keywords
- toxin
- binding protein
- immuno
- protein conjugates
- conjugates including
- Prior art date
Links
- 229940045799 anthracyclines and related substance Drugs 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 230000024033 toxin binding Effects 0.000 title 1
- 239000002596 immunotoxin Substances 0.000 abstract 1
- 231100000654 protein toxin Toxicity 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18199879.0A EP3636284A1 (en) | 2018-10-11 | 2018-10-11 | Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications |
| PCT/EP2019/077644 WO2020074724A1 (en) | 2018-10-11 | 2019-10-11 | Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021003136A true MX2021003136A (es) | 2021-08-19 |
Family
ID=63833918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021003136A MX2021003136A (es) | 2018-10-11 | 2019-10-11 | Conjugados de proteinas de union a toxinas que comprenden antraciclinas, y uso de los mismos en aplicaciones inmunooncologicas. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210379194A1 (https=) |
| EP (2) | EP3636284A1 (https=) |
| JP (1) | JP7607556B2 (https=) |
| KR (1) | KR20210075085A (https=) |
| CN (1) | CN112805037A (https=) |
| AU (1) | AU2019358518A1 (https=) |
| BR (1) | BR112021006269A2 (https=) |
| CA (1) | CA3112848A1 (https=) |
| EA (1) | EA202190653A1 (https=) |
| MX (1) | MX2021003136A (https=) |
| PH (1) | PH12021550750A1 (https=) |
| WO (1) | WO2020074724A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024540099A (ja) | 2021-10-28 | 2024-10-31 | ライエル・イミュノファーマ・インコーポレイテッド | Ｒｏｒ１結合タンパク質を発現する細胞を培養する方法 |
| WO2023217227A1 (zh) | 2022-05-12 | 2023-11-16 | 先声再明医药有限公司 | 喜树碱类衍生物及配体-药物偶联物 |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2777714A1 (en) | 2013-03-15 | 2014-09-17 | NBE-Therapeutics LLC | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme |
| SG11201705041WA (en) | 2014-12-23 | 2017-07-28 | Nbe-Therapeutics Ag | Binding protein drug conjugates comprising anthracycline derivatives |
| WO2016128410A1 (en) | 2015-02-09 | 2016-08-18 | Nbe Therapeutics Ag | Maytansine-drug conjugates of her- 2 specific binding proteins generated by site specific sortase-enzyme mediated conjugation |
| EA201891066A1 (ru) | 2015-10-30 | 2018-10-31 | ЭнБиИ-ТЕРАПЬЮТИКС АГ | Антитела к ror1 |
| US20190112385A1 (en) | 2015-10-30 | 2019-04-18 | Nbe-Therapeutics Ag | Anti-mesothelin antibodies |
| WO2017127702A1 (en) * | 2016-01-20 | 2017-07-27 | The Scripps Research Institute | Ror2 antibody compositions and related methods |
| SG11201806120WA (en) * | 2016-01-20 | 2018-08-30 | Scripps Research Inst | Ror1 antibody compositions and related methods |
| WO2017125815A2 (en) * | 2016-01-22 | 2017-07-27 | MabQuest SA | Immunological reagents |
| CA3035806A1 (en) * | 2016-09-07 | 2018-03-15 | University Of Canberra | Lysine specific histone demethylase-1 inhibitors and uses therefor |
| WO2018103739A1 (zh) * | 2016-12-09 | 2018-06-14 | 凯惠科技发展(上海)有限公司 | 抗体药物偶联物、制备方法、中间体、药物组合物及应用 |
| KR102771835B1 (ko) * | 2017-06-20 | 2025-02-26 | 비바솔, 인코포레이티드. | Cd38 항체 약물 접합체 |
| WO2019016381A1 (en) * | 2017-07-20 | 2019-01-24 | Nbe-Therapeutics Ag | MULTISPECIFIC ANTIBODY PRODUCT BINDING TO DIFFERENT ROR1 EPITOPES |
| WO2019016392A1 (en) | 2017-07-20 | 2019-01-24 | Nbe-Therapeutics Ag | HUMAN ANTIBODIES BINDING TO ROR2 |
| EP3665193A1 (en) | 2017-08-07 | 2020-06-17 | NBE Therapeutics AG | Anthracycline-based antibody drug conjugates having high in vivo tolerability |
| GB201721802D0 (en) * | 2017-12-22 | 2018-02-07 | Almac Discovery Ltd | Ror1-specific antigen binding molecules |
-
2018
- 2018-10-11 EP EP18199879.0A patent/EP3636284A1/en not_active Withdrawn
-
2019
- 2019-10-11 MX MX2021003136A patent/MX2021003136A/es unknown
- 2019-10-11 US US17/283,924 patent/US20210379194A1/en active Pending
- 2019-10-11 CA CA3112848A patent/CA3112848A1/en active Pending
- 2019-10-11 EA EA202190653A patent/EA202190653A1/ru unknown
- 2019-10-11 CN CN201980066701.6A patent/CN112805037A/zh active Pending
- 2019-10-11 KR KR1020217010212A patent/KR20210075085A/ko not_active Ceased
- 2019-10-11 WO PCT/EP2019/077644 patent/WO2020074724A1/en not_active Ceased
- 2019-10-11 AU AU2019358518A patent/AU2019358518A1/en active Pending
- 2019-10-11 JP JP2021519849A patent/JP7607556B2/ja active Active
- 2019-10-11 EP EP19783544.0A patent/EP3863681A1/en active Pending
- 2019-10-11 BR BR112021006269-6A patent/BR112021006269A2/pt unknown
-
2021
- 2021-04-05 PH PH12021550750A patent/PH12021550750A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA202190653A1 (ru) | 2021-05-26 |
| CN112805037A (zh) | 2021-05-14 |
| KR20210075085A (ko) | 2021-06-22 |
| AU2019358518A1 (en) | 2021-04-08 |
| JP2022512672A (ja) | 2022-02-07 |
| US20210379194A1 (en) | 2021-12-09 |
| PH12021550750A1 (en) | 2022-02-21 |
| JP7607556B2 (ja) | 2024-12-27 |
| CA3112848A1 (en) | 2020-04-16 |
| EP3863681A1 (en) | 2021-08-18 |
| BR112021006269A2 (pt) | 2021-08-10 |
| EP3636284A1 (en) | 2020-04-15 |
| WO2020074724A1 (en) | 2020-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021003136A (es) | Conjugados de proteinas de union a toxinas que comprenden antraciclinas, y uso de los mismos en aplicaciones inmunooncologicas. | |
| CO2019005966A2 (es) | Esteroides y conjugados de proteínas de los mismos | |
| MX2025006132A (es) | Conjugado de anticuerpo-derivado de pirrolobenzodiazepina | |
| MX2022002111A (es) | Novedosos anticuerpos anti-cldn18.2. | |
| MX394121B (es) | Anticuerpos que se unen a cd39 y sus usos | |
| CU20210096A7 (es) | Moléculas de unión a cd19 | |
| CL2021003580A1 (es) | Compuestos que comprenden un ligando de proteína de activación de fibroblastos y su uso | |
| CL2021003563A1 (es) | Anticuerpos para la unión a psma | |
| CL2021001627A1 (es) | Molécula bifuncional anti-pd-1/sirpa | |
| BR112015027322A8 (pt) | Compostos antissenso conjugados e sua utilização | |
| BR112022011032A2 (pt) | Conjugado de anticorpo-fármaco anti-claudina e uso farmacêutico do mesmo | |
| BR112018073574A2 (pt) | conjugados de anticorpo-fármaco anti-cmet e métodos para a sua utilização | |
| MX2018010247A (es) | Nuevos conjugados de amanitina. | |
| MX2017007585A (es) | Anticuerpos anti-c10orf54 y usos de los mismos. | |
| CO2020006453A2 (es) | Anticuerpos anti-cxcr5 y composiciones y usos de los mismos | |
| CL2008002381A1 (es) | Oligonucleotido inmunoestimulador; composicion farmaceutica que lo comprende; y su uso para tratar un trastorno o afeccion en un sujeto, incluyendo cancer. | |
| BR112018075651A2 (pt) | anticorpos anti-cd98 e conjugados anticorpo fármaco | |
| PH12021550289A1 (en) | Ox40-binding polypeptides and uses thereof | |
| MX2020003093A (es) | Anticuerpos anti-cd19 novedosos. | |
| IL292766A (en) | Antibody-drug conjugates targeting claudin 18.2 | |
| MX2019008917A (es) | Composiciones farmaceuticas para terapia de combinacion. | |
| CL2019000019A1 (es) | Anticuerpos con baja inmunogenicidad y uso de los mismos | |
| MX2024015391A (es) | Molecula de union a antigeno que se une especificamente a dll3 y cd3, y su uso farmaceutico | |
| CL2020002459A1 (es) | Variantes de anticuerpo c-terminales | |
| EP3959242A4 (en) | ANTRACYCLINE ANTIBODY-DRUG CONJUGATES AND THEIR USES |